CAS:10418-03-8 is the unique Chemical Abstracts Service (CAS) Registry Number assigned to stanozolol, a synthetic anabolic steroid derived from dihydrotestosterone (DHT). Stanozolol is well-known in the medical and athletic communities for its ability to enhance performance and increase muscle mass. It was originally developed by Winthrop Laboratories in 1962 and has since been marketed under various trade names, including Winstrol and Stromba.
Stanozolol stands out due to its anabolic properties, which are significantly stronger than its androgenic effects. This characteristic makes it particularly useful in clinical settings for treating conditions that lead to muscle wasting, such as cachexia and certain anemias. It is also employed to stimulate appetite and increase muscle growth in patients with chronic illnesses.
In the athletic world, stanozolol is often used for its performance-enhancing effects. It promotes muscle growth, increases red blood cell production, and enhances bone density, which collectively improve strength, endurance, and recovery times. Unlike many other anabolic steroids, stanozolol can be taken orally as well as by injection, providing flexibility in administration.
Despite its benefits, stanozolol use is accompanied by potential side effects and health risks. Common adverse effects include liver damage, cardiovascular issues, and hormonal imbalances. Due to its potent nature and potential for misuse, stanozolol is classified as a controlled substance in many countries, and its use is heavily regulated in sports. The World Anti-Doping Agency (WADA) lists stanozolol as a banned substance, and athletes caught using it face severe penalties, including suspensions and disqualifications.
In conclusion, stanozolol (CAS:10418-03-8) is a powerful anabolic steroid with significant medical and athletic applications. While beneficial in certain contexts, its use must be carefully managed to avoid serious health risks and adhere to regulatory standards.
